Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda withdraws Actos in France as it awaits EMA decision

This article was originally published in Scrip

Executive Summary

Takeda is withdrawing its pioglitazone-containing products Actos and Competact in France, at the request of Afssaps, the French health regulatory authority. This follows Afssaps' recent decision to suspend the use of pioglitazone containing products for the treatment of type 2 diabetes. The same decision was taken shortly after by the German authorities, although the Japanese drug-maker has yet to announce a similar move in Germany.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts